MI, CD3 counts, and TILs aid staging of IIIb and IIIc patients in predicting their survival. Patients with staging of IIIb and IIIc are represented in (A). Their survival capabilities cannot be distinguished using only staging (P = 0.59). By incorporating MI, CD3, and TILs (B–D) in the model, it is possible to improve the ability to separate stage IIIb/IIIc patients based on their survival (P = 0.0009, P = 0.0139, and P = 0.0178, respectively).